An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma

• Main Authors: Astrid De Meulenaere (Author), Tijl Vermassen (Author), David Creytens (Author), Stijn De Keukeleire (Author), Tim Delahaye (Author), Philippe Deron (Author), Fréderic Duprez (Author), Samson Fung (Author), Patrick Pauwels (Author), Liesbeth Ferdinande (Author), Sylvie Rottey (Author)
• Format: Book
• Published: Wiley, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract CD70 is expressed in up to 80% of nasopharyngeal carcinoma (NPC) cases. Cusatuzumab is a humanized anti‐CD70 monoclonal antibody, with dual action mechanisms: induction of cytotoxicity against CD70+ tumor cells and reduction in CD70‐CD27 signaling mediated immune evasion. The aim of this st...